Published in Br J Cancer on April 07, 2003
Environmental causes of esophageal cancer. Gastroenterol Clin North Am (2009) 2.80
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Genital HPV infection and related lesions in men. Prev Med (2011) 1.19
InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst (2012) 1.09
Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res (2010) 1.09
More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population. BMC Infect Dis (2006) 1.03
The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agent Cancer (2007) 1.03
Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis. BMC Cancer (2014) 0.95
Human papillomavirus in upper digestive tract tumors from three countries. World J Gastroenterol (2011) 0.91
HPV frequency in penile carcinoma of Mexican patients: important contribution of HPV16 European variant. Int J Clin Exp Pathol (2013) 0.80
HPV seropositivity joints with susceptibility loci identified in GWASs at apoptosis associated genes to increase the risk of Esophageal Squamous Cell Carcinoma (ESCC). BMC Cancer (2014) 0.76
Role of human papillomavirus and cell cycle-related variants in squamous cell carcinoma of the oropharynx. J Biomed Res (2010) 0.75
Human papillomavirus as a potential risk factor for gastric cancer: a meta-analysis of 1,917 cases. Onco Targets Ther (2016) 0.75
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Head and neck cancer. N Engl J Med (2001) 7.32
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst (1994) 3.95
Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol (1994) 2.52
Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer (2001) 2.35
Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl (2000) 2.23
Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis (1995) 2.21
A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol (2002) 1.90
Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res (2001) 1.89
Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol (2001) 1.67
Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol (2002) 1.56
Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ (1997) 1.55
Papillomavirus in esophageal papillomas and carcinomas. Int J Cancer (1999) 1.29
Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis (1995) 1.27
Asymptomatic penile HPV infection: a prospective study. Int J STD AIDS (2000) 1.23
Identification of human papillomavirus seroconversions. J Gen Virol (1995) 1.14
Mapping of linear epitopes of human papillomavirus type 16: the E1, E2, E4, E5, E6 and E7 open reading frames. Int J Cancer (1990) 1.13
Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J Natl Cancer Inst (1999) 1.11
A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur J Cancer Prev (1998) 1.11
Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. BMJ (1995) 1.09
A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res (1997) 1.05
Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. J Infect Dis (1996) 1.04
Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: analysis of primary tumors and lymph nodes. J Med Virol (2000) 1.03
Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer (2000) 1.02
An interlaboratory study to determine the presence of human papillomavirus DNA in esophageal carcinoma from China. Int J Cancer (1999) 1.02
Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J Infect Dis (1999) 0.98
The role of the human papilloma virus in esophageal cancer. Pathology (1998) 0.94
Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia. J Med Virol (2000) 0.93
Absence of human papillomavirus genomic sequences detected by the polymerase chain reaction in oesophageal and gastric carcinomas in Japan. Mol Pathol (1997) 0.93
Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations. Int J Cancer (1996) 0.92
Human papillomavirus type 16 DNA in esophageal carcinomas from Alaska Natives. Int J Cancer (1997) 0.91
Absence of human papillomavirus DNA detected by polymerase chain reaction in French patients with esophageal carcinoma. Gastroenterology (1995) 0.91
No evidence of known types of human papillomavirus in squamous cell cancer of the oesophagus in a low-risk area. Rotterdam Oesophageal Tumour Study Group. Eur J Cancer (1997) 0.90
Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. Sex Transm Infect (1998) 0.89
Human papillomavirus DNA and p53 status in penile carcinomas. Int J Cancer (1998) 0.89
Sequence variations and viral genomic state of human papillomavirus type 16 in penile carcinomas from Ugandan patients. J Gen Virol (1997) 0.86
Association of human papillomavirus type 11 with carcinoma of the penis. Urology (1998) 0.86
Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. J Med Virol (1995) 0.85
Laboratory techniques in the investigation of human papillomavirus infection. Genitourin Med (1992) 0.84
Anogenital premalignant and malignant tumors (including Buschke-Löwenstein tumors). Clin Dermatol (1997) 0.82
Evaluation of the role of human papillomavirus in oesophageal squamous cell carcinoma in Belgium. Acta Gastroenterol Belg (2000) 0.82
How strong and how wide is the link between HPV and oropharyngeal cancer? Lancet (2000) 0.82
Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer. Am J Obstet Gynecol (2002) 0.82
A prospective study of antibody responses to defined epitopes of human papillomavirus (HPV) type 16 in relationship to genital and anorectal presence of HPV DNA. Clin Diagn Lab Immunol (1994) 0.81
Absence of human papillomavirus DNA from esophageal carcinoma as determined by multiple broad spectrum polymerase chain reactions. J Med Virol (1995) 0.79
Human papillomavirus-associated penile squamous cell carcinoma in HIV-positive patients. Am J Surg Pathol (1999) 0.79
Human papillomavirus and urological tumours: I. Basic science and role in penile cancer. BJU Int (1999) 0.78
Cell transformation by animal papillomaviruses. J Gen Virol (1992) 0.77
Serum antibodies to HPV 16 virus-like particles are not associated with penile cancer in Chinese males. Viral Immunol (1996) 0.77
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology (1996) 3.54
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol (2001) 2.71
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol (2005) 2.31
How to avoid false-negative dynamic sentinel node procedures in penile carcinoma. J Urol (2004) 2.29
Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl (2000) 2.23
Quality of life in colorectal cancer. Stoma vs. nonstoma patients. Dis Colon Rectum (1995) 2.15
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst (1995) 2.01
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut (1997) 1.88
Gastric non-Hodgkin lymphomas of mucosa-associated lymphoid tissue are not associated with more aggressive Helicobacter pylori strains as identified by CagA. Am J Clin Pathol (1996) 1.84
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol (2011) 1.73
Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol (2005) 1.70
Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol (2006) 1.67
Critical appraisal of the PADUA classification and assessment of the R.E.N.A.L. nephrometry score in patients undergoing partial nephrectomy. J Urol (2011) 1.64
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer (2000) 1.58
Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ (1997) 1.55
Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. Tumour Biol (1994) 1.54
A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer (1998) 1.49
Antibodies against synthetic peptides react with the second Epstein-Barr virus-associated nuclear antigen. EMBO J (1985) 1.48
No serological evidence for non-sexual spread of HPV16. Lancet (1994) 1.47
Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol (2008) 1.45
Sequential treatment for recurrent localized prostate cancer. J Surg Oncol (2008) 1.45
A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol (1997) 1.42
[Incidence and treatment of prostatic carcinoma in the region of the Comprehensive Cancer Center Amsterdam, 1989-1994]. Ned Tijdschr Geneeskd (1996) 1.40
An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology (2004) 1.40
Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis (1998) 1.39
[Internal radiotherapy in prostatic carcinoma; disappointing long-term results of retropubic Iodine-125 implantation]. Ned Tijdschr Geneeskd (1996) 1.38
Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int J Cancer (1985) 1.38
The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC). Int J Cancer (1996) 1.35
[Less mutilating treatment of penile carcinoma]. Ned Tijdschr Geneeskd (2005) 1.35
Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol (2001) 1.33
Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology (1997) 1.30
HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer (2007) 1.30
Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology (2005) 1.27
Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol (1999) 1.26
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer (2007) 1.25
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis (1990) 1.25
Upper urinary tract cancer: location is correlated with prognosis. Eur Urol (2005) 1.24
Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol (2001) 1.23
A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples. J Clin Microbiol (2000) 1.23
A trial of consent procedures for future research with clinically derived biological samples. Br J Cancer (2009) 1.22
Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol (1999) 1.22
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer (2002) 1.20
Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol (2001) 1.20
EAU Guidelines on Penile Cancer. Eur Urol (2004) 1.19
Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol (2005) 1.18
Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol (1999) 1.16
Sarcomatoid squamous cell carcinoma of the penis: a clinical and pathological study of 5 cases. J Urol (2004) 1.16
Morbidity of dynamic sentinel node biopsy in penile carcinoma. J Urol (2005) 1.15
Identification of human papillomavirus seroconversions. J Gen Virol (1995) 1.14
Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Epidemiology (1998) 1.13
Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review. Ann Oncol (2010) 1.12
Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J Natl Cancer Inst (1999) 1.11
Lymphoblastoid cell lines and Burkitt-lymphoma-derived cell lines differ in the expression of a second Epstein-Barr virus encoded nuclear antigen. Int J Cancer (1986) 1.10
Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann Oncol (1994) 1.10
Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol (1996) 1.09
Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. Gut (1994) 1.09
Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study. Cancer Causes Control (1993) 1.07
[The course of prostatic carcinoma]. Ned Tijdschr Geneeskd (1995) 1.07
[Iodine-125 implantation in localized cancer of the prostate; too early for rejoicing]. Ned Tijdschr Geneeskd (1998) 1.07
Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev (2000) 1.06
Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer (2000) 1.06
Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer (1995) 1.06
A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res (1997) 1.05
Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology (1995) 1.05
Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer (1995) 1.04
Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun (2002) 1.04
Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989. Int J Cancer (1998) 1.04
Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2002) 1.04
Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas. Int J Cancer (1987) 1.03
Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microbiol (1991) 1.03
Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis (1996) 1.03
A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer (1996) 1.03
Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol (2000) 1.02
Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev (2000) 1.02
Structural analysis of the human papillomavirus type 16-E2 transactivator with antipeptide antibodies reveals a high mobility region linking the transactivation and the DNA-binding domains. Nucleic Acids Res (1991) 1.01
Epidemiology of human papillomavirus infection. Scand J Urol Nephrol Suppl (2000) 1.01
Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol (1989) 1.01
Comparison of four different assays for determination of serum S-100B. Int J Biol Markers (2005) 1.00
Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol (1994) 1.00
The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. J Gen Virol (1995) 1.00